Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedMar 3, 2021Dacarbazine for Injection USPLack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance...Teva Pharmaceuticals USA · D-0271-2021Class IITerminatedMar 3, 2021Irinotecan Hydrochloride InjectionCGMP Deviations: based on a Warning Letter received by the manufacturer of the recalled product for inadequate out-of specification investigations, complaint and the...Areva Pharmaceuticals Inc · D-0270-2021Class IOngoingMar 3, 2021ManukaGuard Medical Grade Manuka Honey Allercleanse Nasal SprayMicrobial Contamination of Non-Sterile Products: Product confirmed to have yeastNDAL Mfg Inc. · D-0269-2021Class ITerminatedMar 3, 2021BD ChloraPrep Hi-Lite Orange 2% w/v chlorhexidine gluconateNon-sterility: Product is being recalled to climatic Zone IV regions of the world where at the labeled storage conditions of 30*C/75% Relative Humidity for more than 6...CareFusion 213, LLC · D-0268-2021Class ITerminatedMar 3, 2021ChloraPrep One-Step 2% w/v chlorhexidine gluconateMicrobial Contamination of Non-Sterile Product: Product is being recalled to climatic Zone IV regions of the world where at the labeled storage conditions of 30*C/75%...CareFusion 213, LLC · D-0267-2021Class ITerminatedMar 3, 2021ChloraPrep With Tint 2% w/v chlorhexidine gluconateMicrobial Contamination of Non-Sterile Products:Product is being recalled to climatic Zone IV regions of the world where at the labeled storage conditions of 30*C/75%...CareFusion 213, LLC · D-0266-2021Class ITerminatedMar 3, 2021BD ChloraPrep ClearNon-sterility: Product is being recalled to climatic Zone IV regions of the world where at the labeled storage conditions of 30*C/75% Relative Humidity for more than 6...CareFusion 213, LLC · D-0265-2021Class IITerminatedFeb 24, 2021Cephalexin for Oral SuspensionCGMP Deviations: Individual Unidentified impurities results of the product was found at higher side of the specification limit.Ascend Laboratories LLC · D-0264-2021Class IITerminatedFeb 24, 2021Cephalexin for Oral SuspensionCGMP Deviations: Individual Unidentified impurities results of the product was found at higher side of the specification limit.Ascend Laboratories LLC · D-0263-2021Class IIITerminatedFeb 24, 2021AuryxiaFailed Dissolution SpecificationsAkebia Therapeutics dba Keryx Biopharmaceutials, Inc · D-0260-2021Class IITerminatedFeb 24, 2021Meclizine HCl TabletsFailed Dissolution SpecificationsWilshire Pharmaceuticals Inc · D-0259-2021Class IITerminatedFeb 24, 2021Meclizine HCl TabletsFailed Dissolution SpecificationsWilshire Pharmaceuticals Inc · D-0258-2021Class IITerminatedFeb 24, 2021Sulfur Ointment 10%Labeling: Label Mix-Up. THe English label with Drug Facts panel for Camphor was incorrectly placed on product.DLC Laboratories, Inc · D-0257-2021Class ITerminatedFeb 24, 2021OPTIMUS LUBRICANTS Instant Hand SanitizerChemical Contamination: Products contain methanol and were below the label claim for ethanol contentLiq-E S.A. De C.V. · D-0256-2021Class ITerminatedFeb 24, 2021OPTIMUS LUBRICANTS Instant Hand SanitizerChemical Contamination: Products contain methanol and were below the label claim for ethanol contentLiq-E S.A. De C.V. · D-0255-2021Class ITerminatedFeb 24, 2021OPTIMUS LUBRICANTS Instant Hand SanitizerChemical Contamination: Products contain methanol and were below the label claim for ethanol contentLiq-E S.A. De C.V. · D-0254-2021Class ITerminatedFeb 24, 2021OPTIMUS LUBRICANTS Instant Hand SanitizerChemical Contamination: Products contain methanol and were below the label claim for ethanol contentLiq-E S.A. De C.V. · D-0253-2021Class IOngoingFeb 17, 2021Enoxaparin Sodium InjectionLabeling; Label Mixup; syringe barrels may contain markings for 100 mg/mL (corresponding to 100 mg/mL strength) instead of 150 mg/mL (corresponding to 120 mg/0.8mL...Apotex Corp. · D-0262-2021Class IOngoingFeb 17, 2021Enoxaparin Sodium InjectionLabeling; Label Mixup; syringe barrels may containing markings for 150 mg/mL (corresponding to 120 mg/0.8mL strength) instead of 100 mg/mL markings (corresponding to 100...Apotex Corp. · D-0261-2021Class IITerminatedFeb 17, 2021Lidocaine/TetracaineSuperpotent Drug. Lidocaine higher concentration than listedStanley Specialty Pharmacy Compounding and Wellness Center · D-0252-2021Class IIITerminatedFeb 17, 2021Pantoprazole Sodium for Injection 40mg/vial For I.V. infusion onlyFailed Impurity/Degradation SpecificationsSun Pharmaceutical Industries Inc · D-0251-2021Class IIITerminatedFeb 17, 2021Glycopyrrolate InjectionLabeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vialsAccord Healthcare, Inc. · D-0250-2021Class IIOngoingFeb 10, 2021Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level.Nostrum Laboratories Inc · D-0249-2021Class IITerminatedFeb 10, 2021Acetaminophen Injection 1Discoloration and failed pH specificationsAuroMedics Pharma LLC · D-0248-2021Class IIITerminatedFeb 10, 2021Oseltamivir Phosphate for Oral SuspensionFailed Impurities/Degradation Specifications; Out-of-specification test results observed for Impurity C at 9 month long-term stability time point.Lupin Pharmaceuticals Inc. · D-0247-2021Class IITerminatedFeb 10, 2021Nortriptyline HCl CapsulesCGMP deviations.Taro Pharmaceuticals U.S.A., Inc. · D-0246-2021Class ITerminatedFeb 3, 2021Ketorolac Tromethamine InjectionPresence of Particulate Matter - found in reserve sample vials at the firm.Fresenius Kabi USA, LLC · D-0245-2021Class IIITerminatedFeb 3, 2021Phytonadione Tablets 5mgFailed Impurities/Degradation Specifications:Out of specification during the 24 month stability testing of Impurity D.Bausch Health Companies, Inc. · D-0244-2021Class IIITerminatedFeb 3, 2021MephytonFailed Impurities/Degradation Specifications:Out of specification during the 24 month stability testing of Impurity D.Bausch Health Companies, Inc. · D-0243-2021Class IIITerminatedFeb 3, 2021Testosterone Cypionate InjectionIncorrect Labeling: Incorrect lot number on secondary packagingSun Pharmaceutical Industries Inc · D-0242-2021Class IITerminatedFeb 3, 2021IMC Wash-Free Hand SanitizerCGMP Deviations: product manufactured at the same facility that produced product that FDA sampled and found to be subpotent for ethanol and contained methanol.Shane Erickson Inc · D-0241-2021Class IITerminatedFeb 3, 2021IMC Wash-Free Hand SanitizerCGMP Deviations: product manufactured at the same facility that produced product that FDA sampled and found to be subpotent for ethanol and contained methanol.Shane Erickson Inc · D-0240-2021Class IITerminatedFeb 3, 2021IMC Wash-Free Hand SanitizerCGMP Deviations: product manufactured at the same facility that produced product that FDA sampled and found to be subpotent for ethanol and contained methanol.Shane Erickson Inc · D-0239-2021Class IITerminatedJan 27, 2021Ceftazidime Sterile Ophthalmic Solution for Injection Preservative Free 11.25mg / 0.5mlLack of Assurance of Sterility; the media used to conduct post-compounding sterility testing for the Methotrexate product was expired.Edge Pharma, LLC · D-0238-2021Class IITerminatedJan 27, 2021HUMAN CHORIONIC GONADOTROPIN 1CGMP deviations: Lack of potency testing.Complete Pharmacy and Medical Solutions, LLC. · D-0237-2021Class IITerminatedJan 27, 2021HUMAN CHORIONIC GONADOTROPIN 5CGMP deviations: Lack of potency testing.Complete Pharmacy and Medical Solutions, LLC. · D-0236-2021Class IITerminatedJan 27, 2021HUMAN CHORIONIC GONADOTROPIN 6CGMP deviations: Lack of potency testing.Complete Pharmacy and Medical Solutions, LLC. · D-0235-2021Class IITerminatedJan 27, 2021HUMAN CHORIONIC GONADOTROPIN 11CGMP deviations: Lack of potency testing.Complete Pharmacy and Medical Solutions, LLC. · D-0234-2021Class IITerminatedJan 27, 2021Refresh Relieva PF Preservative-Free Lubricant Eye Drops 0.33 fl ozLabeling: Missing instructions for use insertAllergan, PLC. · D-0233-2021Class IITerminatedJan 27, 2021Nitrofurantoin Capsules USPFailed Dissolution SpecificationsAmerican Health Packaging · D-0232-2021